Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves’ disease
Recently, it has been confirmed that circulating miRNAs play an important role in disease pathogenesis and can be biomarkers of many autoimmune diseases. However, the knowledge about circulating miRNAs in Graves’ disease (GD) is very limited. In this study, we aimed to identify circulating miRNAs as potential biomarkers of GD.
We recruited 68 participants who met the criteria for GD and healthy controls. The expression profile of miRNAs in plasma was detected using microarrays. We found five interesting miRNAs were differentially expressed between GD and control group and futher validated their relative expression by quantitative real-time PCR. According to their putative target genes predicted by the TargetScan database, we also performed Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses to predict their potential functions and related pathways.
Microarray data showed that five miRNAs were differentially expressed in GD and control plasma samples. Among them, miR-16-1-3p, miR-122-5p, miR-221-3p, and miR-762 were upregulated in GD (P < 0.001). In validation stage, we found miR-144-3p was significantly decreased and miR-762 was markedly upregulated in GD plasma (P < 0.01). In addition, miR-762 expression was positively associated with levels of FT3 (r = 0.307, P = 0.038) as well as TRAb (r = 0.302, P = 0.042). The receiver-operating characteristic (ROC) curve analysis showed that both miR-144-3p and miR-762 displayed good sensitivity and specificity in discriminating the GD patients from the rest of subjects with the area under the ROC curve (AUC) of 0.761 (P = 0.001, 95% CI = 0.648–0.875) and 0.737 (P = 0.001, 95% CI = 0.618–0.857), respectively. Combination of miR-144-3p and miR-762 could better discriminate GD patients from healthy controls with AUC of 0.861 (P < 0.001, 95% CI = 0.775–0.947).
We first demonstrated that aberrant levels of plasmic miR-144-3p and miR-762 were associated with GD, which may be biomarkers for GD diagnosis.
KeywordsGraves’ disease MicroRNA Plasma Biomarker
The authors would like to thank all of the participants who took part in the studies.
This project was supported by grants from the National Natural Science Foundation of China (Nos 81670722 and 81873636), and Natural Science Foundation of Shanghai (18ZR1433800).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and consent to participate
This work was approved by the Ethics Committee of Jinshan Hospital, Fudan University. Written informed consents were obtained from all participants.
- 1.F. Shehjar, D. Afroze, R.A. Misgar, S.A. Malik, B.A. Laway, Association of FoxP3 promoter polymorphisms with the risk of Graves’ disease in ethnic Kashmiri population. Gene (2018). https://doi.org/10.1016/j.gene.2018.06.023
- 13.C. Castro-Villegas, C. Perez-Sanchez, A. Escudero, I. Filipescu, M. Verdu, P. Ruiz-Limon, M.A. Aguirre, Y. Jimenez-Gomez, P. Font, A. Rodriguez-Ariza, J.R. Peinado, E. Collantes-Estevez, R. Gonzalez-Conejero, C. Martinez, N. Barbarroja, C. Lopez-Pedrera, Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res. Ther. 17, 49 (2015)CrossRefGoogle Scholar
- 18.L. Zheng, C. Zhuang, X. Wang, L. Ming, Serum miR-146a, miR-155, and miR-210 as potential markers of Graves’ disease. J. Clin. Lab. Anal. 32 (2018). https://doi.org/10.1002/jcla.22266
- 19.R. Martinez-Hernandez, M. Sampedro-Nunez, A. Serrano-Somavilla, A.M. Ramos-Levi, H. de la Fuente, J.C. Trivino, A. Sanz-Garcia, F. Sanchez-Madrid, M. Marazuela, A. MicroRNA, Signature for evaluation of risk and severity of autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 103, 1139–1150 (2018)CrossRefGoogle Scholar
- 22.Y.J. Su, I.C. Lin, L. Wang, C.H. Lu, Y.L. Huang, H.C. Kuo, Next generation sequencing identifies miRNA-based biomarker panel for lupus nephritis. Oncotarget 9, 27911–27919 (2018)Google Scholar
- 23.M. Liguori, N. Nuzziello, F. Licciulli, A. Consiglio, M. Simone, R.G. Viterbo, T.M. Creanza, N. Ancona, C. Tortorella, L. Margari, G. Grillo, P. Giordano, S. Liuni, M. Trojano, Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Hum. Mol. Genet. 27, 66–79 (2018)CrossRefGoogle Scholar
- 25.Z.X. Cheng, Y.X. Song, Z.Y. Wang, Y. Wang, Y. Dong, miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur. Rev. Med. Pharmacol. Sci. 21, 4079–4086 (2017)Google Scholar
- 26.C. Wu, B. Xu, Y. Zhou, M. Ji, D. Zhang, J. Jiang, C. Wu, Correlation between serum IL-1beta and miR-144-3p as well as their prognostic values in LUAD and LUSC patients. Oncotarget 7, 85876–85887 (2016)Google Scholar
- 28.Y. Zhao, Z. Xie, J. Lin, P. Liu, MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met. Am. J. Transl. Res. 9, 2437–2446 (2017)Google Scholar
- 35.D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016)CrossRefGoogle Scholar